Corporate | 26 February 2010 16:18
Eckert & Ziegler Strahlen- und Medizintechnik AG / Miscellaneous
26.02.2010 16:18
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 26.2.2010 - In light of the announcement of several resignations
from the board of directors at International Brachytherapy (IBt), Eckert &
Ziegler, a major shareholder of IBt, confirms its intention to nominate
independent directors as replacements for the resigning incumbents. Eckert
& Ziegler (ISIN DE0005659700) is not seeking for itself a majority in the
board. The company hence strongly rejects speculations in the press about
potential corporate governance issues at IBt.
'The independent directors and the management team will also in the future
clearly maintain a majority in the board of directors of IBt', said Andreas
Eckert, CEO of Eckert & Ziegler. 'Any suspicions that Eckert & Ziegler
intends to run IBt as a puppet company are nonsense. Eckert & Ziegler has
no desire or intention to micromanage IBt. We are interested in growth and
profitability, not in status and favoritism. The move of Eckert & Ziegler
and SMI to enlarge its board influence in the upcoming shareholder meeting
of 3 March is defensive and solely driven by the desire to implement a
sustainable winning culture.
Eckert added: 'It is indicative that the resignations, as well as the
sudden public worries about corporate governance issues, have come
exclusively from persons that were responsible for the year-long agony of
IBt prior to the arrival of Eckert & Ziegler. By contrast, the new
independent director and the new management team that came on board later,
have not voiced any concern about the proposed changes. They understand
that the existing relations of Eckert & Ziegler and SMI are not a threat,
but an opportunity for the prospects of IBt.'
Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail: karolin.riehle@ezag.de,
www.ezag.de
26.02.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------